Anti-GFAP R416WT Antibody [N206B/9 (Formerly sold as S206B-9)]

(No reviews yet) Write a Review
SKU:
STMA00142
Antibody Type:
Monoclonal
Applications:
WB
Applications:
IHC
Applications:
ICC/IF
Reactivity:
Human
Reactivity:
Mouse
Reactivity:
Rat
Host Species:
Mouse
Isotype:
IgG1
  • Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-GFAP R416WT Monoclonal Antibody, Clone N206B/9 (STMA00142). Tissue: Neuroblastoma cells (SH-SY5Y). Species: Human. Fixation: 4% PFA for 15 min. Primary Antibody: Mouse Anti-GFAP R416WT Monoclonal Antibody (STMA00142) at 1:200 for overnight at 4°C with slow rocking. Secondary Antibody: AlexaFluor 488 at 1:1000 for 1 hour at RT.
  • Western Blot analysis of Rat Brain Membrane showing detection of GFAP protein using Mouse Anti-GFAP Monoclonal Antibody, Clone N206B/9 (STMA00142). Primary Antibody: Mouse Anti-GFAP Monoclonal Antibody (STMA00142) at 1:250.
Frequently bought together:

Description

GFAP R416WT Antibody [N206B/9 (Formerly sold as S206B-9)]

GFAP R416WT Antibody [N206B/9 (Formerly sold as S206B-9)] is a mouse monoclonal antibody directed against GFAP R416WT, offered by Assay Genie for research applications. Reported applications include WB, IHC and ICC/IF. Reported reactivity: Human, Mouse and Rat. Supplied as IgG1, purified by Protein G.

Glial fibrillary acidic protein (GFAP) is a 50 kDa type III intermediate filament protein that serves as a key structural component of astrocytes in the central nervous system. It plays a critical role in maintaining astrocyte architecture and function. GFAP polymerization is regulated through phosphorylation and interactions with calcium-binding proteins such as annexin II-p2 and S-100, enabling dynamic responses to physiological and pathological stimuli. One of the earliest and most prominent astrocytic responses to central nervous system injury is astrogliosis, characterized by astrocyte proliferation and hypertrophy. A hallmark of this process is the upregulation of GFAP expression, making it a widely used biomarker for reactive astrocytes and neuroinflammation. In the context of neurodegenerative diseases—including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis—elevated GFAP levels reflect ongoing glial activation and are associated with disease progression. Notably, autoantibodies against GFAP have been detected in individuals with dementia, suggesting a potential link between astrocytic dysfunction and neuroimmune mechanisms in neurodegeneration. Due to its specificity and responsiveness to neural injury, GFAP is extensively used in both experimental and clinical neuroscience as a diagnostic and prognostic marker. Its role in glial biology and neuroinflammation continues to make it a focal point in the development of therapeutic strategies targeting astrocyte-mediated pathology. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.

View AllClose

0 Reviews

View AllClose